Gilead, Galapagos report positive follow-up data for arthritis drug, but regulatory risk remains
An analyst wrote that while filgotinib's profile appears clean overall, even minor safety imbalances could derail its approval, while a slight imbalance in the number of deaths between the Phase III study arms could also attract scrutiny.